touchPODCAST

touchPODCAST

By touchpodcastScience
Download on the App Store

touchPODCAST episodes

  • Contemporary insights on sickle cell disease complications and recent advances in therapy

    touchPANEL DISCUSSION for touchNEUROLOGY

    Listen to three expert haematologists discuss the management of complications of sickle cell disease, as well as recent advances in therapy.

    The experts

    • Prof. Biree Andemariam, Farmington, CT, USA;
  • Prof. Modupe Idowu, Houston, TX, USA;
  • Prof. Mark C Walters, Oakland, CA, USA;

    • This touchPODCAST is for HCPs only. 

    This activity is funded by an independent medical education grant from Agios Pharmaceuticals Inc., Pfizer and Vertex Pharmaceuticals. This activity is jointly provided by USF Health and touchIME.

    For further information please visit our website: touchNEUROLOGY

    40 min
  • Contemporary insights on sickle cell disease complications and recent advances in therapy

    touchPANEL DISCUSSION for touchCARDIO

    Listen to three expert haematologists discuss the management of complications of sickle cell disease, as well as recent advances in therapy.

    The experts

    • Prof. Biree Andemariam, Farmington, CT, USA;
  • Prof. Modupe Idowu, Houston, TX, USA;
  • Prof. Mark C Walters, Oakland, CA, USA;

    • This touchPODCAST is for HCPs only. 

    This activity is funded by an independent medical education grant from Agios Pharmaceuticals Inc., Pfizer and Vertex Pharmaceuticals. This activity is jointly provided by USF Health and touchIME.

    For further information please visit our website: touchCARDIO

    40 min
  • Contemporary insights on sickle cell disease complications and recent advances in therapy

    touchPANEL DISCUSSION for touchHAEMATOLOGY

    Listen to three expert haematologists discuss the management of complications of sickle cell disease, as well as recent advances in therapy.

    The experts

    • Prof. Biree Andemariam, Farmington, CT, USA;
  • Prof. Modupe Idowu, Houston, TX, USA;
  • Prof. Mark C Walters, Oakland, CA, USA;

    • This touchPODCAST is for HCPs only.

    This activity is funded by an independent medical education grant from Agios Pharmaceuticals Inc., Pfizer and Vertex Pharmaceuticals. This activity is jointly provided by USF Health and touchIME.

    For further information please visit our website: touchHAEMATOLOGY

    40 min
  • New and emerging agents in HER2-negative metastatic breast cancer Implications for current and future practice

    touchPANEL DISCUSSION for touchONCOLOGY

    Listen to three breast cancer experts discuss the expanding targeted treatment options for HER2-negative metastatic breast cancer, with a focus on approved and emerging antibody drug conjugates and considerations for their use in clinical practice. 

    The experts

    • Prof. Giuseppe Curigliano, University of Milan, Milan, Italy
  • Prof. Hope Rugo, University of California, San Francisco, CA, USA
  • Prof. Peter Schmid, Barts Cancer Institute, London, UK

    • This touchPODCAST is for HCPs only.

    This activity is funded by an independent medical education grant from Gilead Sciences, Inc. This activity is jointly provided by USF Health and touchIME.

    For further information visit our website: https://touchoncologyime.org/new-and-emerging-agents-in-her2negative-mbc 

    36 min
  • DOACs and reversal agents for patients experiencing ICH: Latest evidence - touchCARDIOLOGY

    touchEXPERT OPINIONS for touchCARDIOLOGY

    Leading experts share their insights on the impact of intracerebral haemorrhage (ICH) in patients receiving direct oral anticoagulants (DOACs), DOAC-ICH reversal agents and optimizing treatment outcomes.

    The experts:

    • Prof. Hanne Christensen, University of Copenhagen, Denmark
  • Prof. Thorsten Steiner, The Clinical Centre in Frankfurt Höchst, Frankfurt, Germany
  • Dr Truman Milling, The University of Texas at Austin, TX, USA

    • This touchPODCAST is for HCPs only. 

    This activity is funded by an independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.

    For further information visit

    www.touchcardio.com

    37 min
  • DOACs and reversal agents for patients experiencing ICH: Latest evidence - touchNEUROLOGY

    touchEXPERT OPINIONS for touchNEUROLOGY

    Leading experts share their insights on the impact of intracerebral haemorrhage (ICH) in patients receiving direct oral anticoagulants (DOACs), DOAC-ICH reversal agents and optimizing treatment outcomes.

    The experts:

    • Prof. Hanne Christensen, University of Copenhagen, Denmark
  • Prof. Thorsten Steiner, The Clinical Centre in Frankfurt Höchst, Frankfurt, Germany
  • Dr Truman Milling, The University of Texas at Austin, TX, USA

    • This touchPODCAST is for HCPs only. 

    This activity is funded by an independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.

    For further information visit:

    www.touchneurology.com

     

    37 min
  • Key considerations in the management of irAEs with ICIs in advanced or recurrent endometrial cancer

    touchMDT for touchONCOLOGY

    Listen to key experts from a multidisciplinary team discuss the case-based implementation of

    immune checkpoint inhibitors in endometrial cancer through shared decision making.

    The multidisciplinary team:

    • Gynaecological oncologist: Prof. Christian Marth, Innsbruck, Austria
  • Medical oncologist: Dr Ilaria Colombo, Bellinzona, Switzerland

    • This touchPODCAST is for HCPs only.

    This activity is funded by an unrestricted independent medical educational grant from GlaxoSmithKline. This activity is provided by touchIME.

    For further information visit our website: 

    https://touchoncology.com/education/mdt-for-ici-in-ec/

    16 min
  • Importance of shared decision making in the management of endometrial cancer

    touchMDT for touchONCOLOGY

    Listen to key experts from a multidisciplinary team discuss key considerations in the management of immune-related adverse events with immune checkpoint inhibitors in advanced or recurrent endometrial cancer

    The multidisciplinary team:

    • Gynaecological oncologist: Prof. Christian Marth, Innsbruck, Austria
  • Medical oncologist: Dr Ilaria Colombo, Bellinzona, Switzerland
  • Pathologist: Dr Tjalling Bosse, Leiden, Netherlands

    • This touchPODCAST is for HCPs only.

    This activity is funded by an unrestricted independent medical educational grant from GlaxoSmithKline. This activity is provided by touchIME.

    For further information visit our website: 

    https://touchoncology.com/education/mdt-for-ici-in-ec/

    13 min
  • Improving outcomes with ICIs in advanced or recurrent endometrial cancer

    touchMDT for touchONCOLOGY

    Listen to key experts from a multidisciplinary team discuss improving outcomes with immune checkpoint inhibitors in advanced or recurrent endometrial cancer.

    The multidisciplinary team:

    • Gynaecological oncologist: Prof. Christian Marth, Innsbruck, Austria
  • Medical oncologist: Dr Ilaria Colombo, Bellinzona, Switzerland

    • This touchPODCAST is for HCPs only.

    This activity is funded by an unrestricted independent medical educational grant from GlaxoSmithKline. This activity is provided by touchIME.

    For further information visit our website: 

    https://touchoncology.com/education/mdt-for-ici-in-ec/

    15 min
  • Optimizing outcomes of JAK inhibition in myelofibrosis: Practical considerations for the clinic - touchHAEMATOLOGY

    touchIN CONVERSATION for touchHAEMATOLOGY

    Listen to Prof. John Mascarenhas (Icahn School of Medicine at Mount Sinai, New York, NY, USA) in conversation with Dr Raajit Rampal (Memorial Sloan Kettering Cancer Center, New York, NY, USA) on how to optimize the use of JAK inhibitors for patients with myelofibrosis. 

    They respond to questions submitted by the HCP audience and provide expert insights on:

    • The key considerations when selecting a first-line JAK inhibitor
  • How to best manage side effects associated with JAK inhibitors
  • The treatment options following failure on a first-line JAK inhibitor 

    • This touchPODCAST is for HCPs only. 

    This activity is funded by an unrestricted independent medical education grant from Bristol Myers Squibb. This activity is jointly provided by USF Health and touchIME.

    For further information visit our website: 

    https://touchhaematologyime.org/in-conversation-jak-inhibition-in-myelofibrosis 

    36 min

About touchPODCAST

From the publisher's feed

Welcome to touchPODCAST where you can listen and learn from our expert faculty, hand-picked from the Touch Medical Media family of independent medical websites.